TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00753454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol
Description: Liquid certolizumab pegol administered every two weeks as a single injection (400 mg at Entry, Week 2 \& Week 4, followed by 200 mg every 2 weeks).
Study: NCT00134563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriflunomide
Description: Film-coated tablet~Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriflunomide
Description: Film-coated tablet~Oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for teriflunomide)
Description: Film-coated tablet~Oral administration
Study: NCT03736122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BSG-001
Description: BSG-001 is in solution form, 4mg per vial (2mg/mL) with Inhalation as route of administration using nebulizer.~BSG-001 will be administrated as an approximately 5 - 30 minutes inhalation session daily for 3 cycles (in repeated 28 days cycle).
Study: NCT04264949

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education in the use of smartphone app (Mon coach dos)
Description: In addition to conventional care and the therapeutic education program, GA will benefit from three education sessions (one per week) on the use of the smartphone app mon coach dos

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional care
Description: conventional care and the therapeutic education program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional care
Description: conventional care and the therapeutic education program
Study: NCT01161173

Intervention type: DRUG
Intervention: Erlotinib
Description: Erlotinib was provided in the retail versions of the product.
Study: NCT03017131

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Genetically Engineered NY-ESO-1-specific T Lymphocytes
Description: Given IV and IP

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03219372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin Pill
Description: statin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: placebo
Study: NCT05497570

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenoxicam Injectable Product
Description: After arthrocentesis procedure, 2-ml injection of tenoxicam (Oksamen-L, Mustafa Nevzat İlaç Sanayi, Istanbul, Turkey) to the temporomandibular joint

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenoxicam Injectable Product
Description: After arthrocentesis procedure, 2-ml injection of tenoxicam (Oksamen-L, Mustafa Nevzat İlaç Sanayi, Istanbul, Turkey) to the temporomandibular joint
Study: NCT02086240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XBD173
Description: XBD173 (Emapunil is an anxiolytic drug which acts as a selective agonist at the peripheral benzodiazepine receptor), a drug which binds the TSPO with high affinity.
Study: NCT04124445

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed Radiofrequency Ablation
Description: Radiofrequency ablation, also called rhizotomy, is a nonsurgical, minimally invasive procedure that uses heat to reduce or stop the transmission of pain. Radiofrequency waves ablate, or burn, the nerve that is causing the pain, essentially eliminating the transmission of pain signals to the brain.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed Radiofrequency Ablation
Description: Radiofrequency ablation, also called rhizotomy, is a nonsurgical, minimally invasive procedure that uses heat to reduce or stop the transmission of pain. Radiofrequency waves ablate, or burn, the nerve that is causing the pain, essentially eliminating the transmission of pain signals to the brain.
Study: NCT02740192

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adductor Canal Block
Description: Post-op adductor canal block using Bupivacaine

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periarticular Injection
Description: Intra-op periarticular injection of Ropivacaine

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Periarticular Injection
Description: Intra-op periarticular injection of Ropivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Ropivacaine was used for the periarticular injection
Study: NCT04664933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-arterial administration of neuroprotective agents
Description: Intra-arterial administration of 3-n-butylphthalide for 16 to 24 hours during and after the operation at 17.36 to 26.04 ug/min
Study: NCT02518867

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high intensity iTBS
Description: In intermittent theta burst stimulation pattern (iTBS) will intermittently give a 2 s train of TBS every 10s for a total of 20 times (high intensity , 100% of active motor threshold) TBS for 3 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low intensity iTBS
Description: In intermittent theta burst stimulation pattern (iTBS) will intermittently give a 2 s train of TBS every 10s for a total of 20 times (low intensity, 80% of active motor threshold) TBS for 3 days.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham iTBS
Description: In sham burst stimulation pattern (sham TBS) will intermittently give a sham TBS treatment.
Study: NCT02985996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada
Description: Truvada is intended for the treatment of HIV-1 infection. Truvada is a combination of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg in one tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada
Description: Truvada is intended for the treatment of HIV-1 infection. Truvada is a combination of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg in one tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genvoya
Description: Genvoya is a 1-pill, once-a-day prescription medicine used to treat HIV-1. Genvoya is a combination of 150 mg of elvitegravir, 150 mg of cobicistat, 200 mg of emtricitabine, and 10 mg of tenofovir alafenamid in one tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genvoya
Description: Genvoya is a 1-pill, once-a-day prescription medicine used to treat HIV-1. Genvoya is a combination of 150 mg of elvitegravir, 150 mg of cobicistat, 200 mg of emtricitabine, and 10 mg of tenofovir alafenamid in one tablet.
Study: NCT04516798

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vibration
Description: local and whole-body vibration were applied
Study: NCT02740192

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Ropivacaine
Description: Ropivacaine was used for the periarticular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Bupivacaine was used for the periarticular injection
Study: NCT01027702

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infusion of donor lymphocytes
Description: A donor lymphocyte infusion will be given to provide T cells. There will be a dose escalation: 3 x 10\^4, 4 x 10\^4, 5 x 10\^4, 6 X 10\^4, 8 x 10\^4, and 10 X10\^4 cells/kg body weight. At least three patients will be assessed at each dose to determine safety before dose is increased.
Study: NCT02155023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin dosing

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glucose sensors IR-Glucose Reader (Joanneum Research, Austria), IR-CGM (IMM, Germany)
Study: NCT01068509

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cvac
Description: Cvac consists of autologous dendritic cells (DCs) incubated with the antigen, mannosylated fusion protein (M-FP), to target the DCs to the specific mucin 1 antigen.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cvac
Description: Cvac consists of autologous dendritic cells (DCs) incubated with the antigen, mannosylated fusion protein (M-FP), to target the DCs to the specific mucin 1 antigen.
Study: NCT02766335

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Given IV
Study: NCT02482025

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SMMRT
Description: Includes My HealtheVet registration and enrollment
Study: NCT02903186

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMS
Description: This is an intervention using short mobile messages (SMS)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS
Description: This is an intervention using short mobile messages (SMS)
Study: NCT03463746

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LYRA® gait trainer
Description: The EG will get standard individual physical therapy (5x/week, 45min) whereby three sessions of electromechanical-assisted gait training on LYRA® gait trainer.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard individual physical therapy
Description: The CG will get standard individual physical therapy (5x/week, 45min) without any instrument-based locomotion therapy (i.e. treadmill training, electromechanical/robot-assisted gait training).
Study: NCT04500184

Intervention type: OTHER
Intervention: cardiac rehabilitation
Description: rehabilitation performed by professional trainers
Study: NCT01212809

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cosmoderm 1
Description: Split-face injection of Cosmoderm 1 into vertical lip rhytids and radial cheek lines on one side of face
Study: NCT03095261

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based exercise diary
Description: All participants will have access to a web-based exercise tracking tool called ExTracker. Individuals will be asked to submit their exercise diaries daily for 52 weeks, using the ExTracker program. Upon entering exercise information, participants will receive individual (e.g., You've completed 50% of your exercise sessions this week!) and group-level (e.g., You and the other people in this study are walking across Canada! Next stop - Toronto!) feedback. Should participants cease to use the platform for one week, they will receive an email reminder to re-engage with the platform. Three such emails will be sent to lapsing participants.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Web-based exercise diary
Description: All participants will have access to a web-based exercise tracking tool called ExTracker. Individuals will be asked to submit their exercise diaries daily for 52 weeks, using the ExTracker program. Upon entering exercise information, participants will receive individual (e.g., You've completed 50% of your exercise sessions this week!) and group-level (e.g., You and the other people in this study are walking across Canada! Next stop - Toronto!) feedback. Should participants cease to use the platform for one week, they will receive an email reminder to re-engage with the platform. Three such emails will be sent to lapsing participants.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accelerometer
Description: All participants will be asked to wear the StepsCount Piezo accelerometer, and track the steps per day and bout minutes of MVPA per day measured by the device. Additionally, participants will be mailed an accelerometer (and asked to return their used ones) at study weeks 26 and 52 in order for the researcher to confirm the data inputted into the ExTracker from the device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Accelerometer
Description: All participants will be asked to wear the StepsCount Piezo accelerometer, and track the steps per day and bout minutes of MVPA per day measured by the device. Additionally, participants will be mailed an accelerometer (and asked to return their used ones) at study weeks 26 and 52 in order for the researcher to confirm the data inputted into the ExTracker from the device.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reward
Description: Participants will earn 'virtual rewards' (i.e. a heart badge) each day they track their exercise, for the first six months of the study. In the second six months, participants will crossover to the other therapy, the 'financial incentive' therapy, for six months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentive
Description: Participants will earn financial incentives each day they track their exercise, for the first six months of the study. In the second six months, participants will crossover to the other therapy, the 'virtual rewards' therapy, for six months.
Study: NCT00866541

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: artificial increased resistance (flow proportional pressure support)
Description: respiratory resistance is increased by interpose of an artificial resistance tool in the in- and expiratory airways of the mechanical respirator
Study: NCT01405508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam tablets
Description: 100 mg, intake twice daily (BID) for 7 days during Run-In Period
Study: NCT02433704

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: New Intraosseous
Description: Intraosseous administration of prophylactic antibiotics

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin
Description: Cefazolin 1 gram will be given through an intraosseous cannula, placed into the medial aspect of the proximal tibia, after draping and before skin incision. The cefazolin will be administered as a bolus in 200 mL of normal saline.
Study: NCT04795570

Intervention type: PROCEDURE
Intervention: Transurethral resection of the prostate or bladder
Description: All patients undergoing TUR P/B will undergo a blood draw within 6 months after surgery to determine hormonal status and coagulation disorders.
Study: NCT02766335

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV
Study: NCT01405508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam tablets
Description: 100 mg, intake twice daily (BID) for 7 days during Run-In Period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam bolus
Description: 10 mL (= 100 mg) of Brivaracetam administered intravenously over 2 minutes twice daily (BID) during Evaluation Period
Study: NCT01405508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam bolus
Description: 10 mL (= 100 mg) of Brivaracetam administered intravenously over 2 minutes twice daily (BID) during Evaluation Period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam infusion
Description: 10 mL (= 100 mg) of Brivaracetam diluted in 90 mL 0.9 % isotonic saline sterile solution for intravenous administration infused over 15 minutes twice daily (BID) during Evaluation Period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam infusion
Description: 10 mL (= 100 mg) of Brivaracetam diluted in 90 mL 0.9 % isotonic saline sterile solution for intravenous administration infused over 15 minutes twice daily (BID) during Evaluation Period

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 100 mg twice daily (BID) for 7 days during Run-In Period
Study: NCT03171272

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Inspiratory Muscle Training
Description: Experimental: IMT will include training of the inspiratory muscles five times per week over six weeks, divided into two fiftten-minute sessions of inspiratory training totaling 30 minutes of training. Thresholds regulated at 50% of the subjects' maximal inspiratory pressure values, the load being increased weekly. Associated with the IMT, subjects will participate in the rehabilitation program, when they will perform 7 sessions of physiotherapy per week, totaling 42 sessions, as well as 180 minutes per week of aerobic exercise, for six weeks.~Sham Group: This group will underwent exactly the same protocol but the participants will receive the threshold devices with the minimum resistance of the spring, which will be also concealed. The control group will also participate in the rehabilitation program and undergo the same procedures, except for the load adjustments.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: Experimental: IMT will include training of the inspiratory muscles five times per week over six weeks, divided into two fiftten-minute sessions of inspiratory training totaling 30 minutes of training. Thresholds regulated at 50% of the subjects' maximal inspiratory pressure values, the load being increased weekly. Associated with the IMT, subjects will participate in the rehabilitation program, when they will perform 7 sessions of physiotherapy per week, totaling 42 sessions, as well as 180 minutes per week of aerobic exercise, for six weeks.~Sham Group: This group will underwent exactly the same protocol but the participants will receive the threshold devices with the minimum resistance of the spring, which will be also concealed. The control group will also participate in the rehabilitation program and undergo the same procedures, except for the load adjustments.
Study: NCT01869920

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: Education on breastfeeding

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual care
Description: Usual care
Study: NCT04856072

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: Personalized Deep Brain Stimulation of Fornix
Study: NCT03068507

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trimodal prehabilitation management
Description: Trimodal prehabilitation strategy includes physical exercise (moderate aerobic exercise combined with resistance exercise and respiratory training ), nutritional suggestion and optimization（whey protein supplement）, and psychological therapy, as well as conventional guidance (including preoperative anesthesia assessment, drug treatment recommendations for chronic disease, quit smoking and abstinence).
Study: NCT01405508

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 100 mg twice daily (BID) for 7 days during Run-In Period
Study: NCT00672464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Olanzapine zydis 15 mg QHS for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Olanzapine zydis 15 mg QHS for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Olanzapine zydis 15 mg QHS for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Olanzapine zydis 15 mg QHS for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin capsules will be started at 500 mg twice a day (before breakfast and before dinner) for days 1-3, then 500 mg before breakfast and 1000 mg before dinner for days 4-7, and then 1000 mg twice a day thereafter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin capsules will be started at 500 mg twice a day (before breakfast and before dinner) for days 1-3, then 500 mg before breakfast and 1000 mg before dinner for days 4-7, and then 1000 mg twice a day thereafter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin will be started at 10 mg at bed time for the first week and 20 mg at bedtime thereafter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin will be started at 10 mg at bed time for the first week and 20 mg at bedtime thereafter.
Study: NCT03445494

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brace
Description: A brace to be weared according to protocol

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Normal sling
Description: A normal sling to be weared according to protocol
Study: NCT04691518

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acute Intermittent Hypoxia
Description: 30 minute session of Acute Intermittent Hypoxia

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham Acute Intermittent Hypoxia
Description: 30 minute session of Sham Acute Intermittent Hypoxia
Study: NCT01014442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: 1.5 g PO BID from Days 2 to 30 post-transplantation, 1 g PO BID Days 31 to 90 post-transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: 1.5 g PO BID from Days 2 to 30 post-transplantation, 1 g PO BID Days 31 to 90 post-transplantation
Study: NCT01379599

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: brief motivation intervention
Description: Brief motivation intervention consisting of brief psychosocial counseling (20 minutes at the time of an ER visit)
Study: NCT03286114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200mg IV every 21 days
Study: NCT00821886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: Ixabepilone 40mg/m2 IV infusion over 3 hours on day 1 of cycles 1-6 (all treatment cycles are 21 days in length)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab 8mg/kg IV over 90 minutes for the first infusion (Cycle 1, Day 1) with a 60 minute post-infusion observation period. Subsequent infusions (Day 1 of Cycles 2-6 with all cycles being 21 days in length) 6mg/kg over 30 minutes if the previous dose was well tolerated; peri-operative trastuzumab 6mg/kg IV every 3-4 weeks; post-operative trastuzumab 6mg/kg IV day 1 every 3 weeks until week 52

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC=6 IV per institutional guidelines on Day 1 of Cycles 1-6 (all treatment cycles are 21 days in length)